Equities Analysts Offer Predictions for Innoviva Q2 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for Innoviva in a research note issued to investors on Monday, June 1st. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn $0.56 per share for the quarter, up from their previous forecast of $0.51. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $1.96 per share. HC Wainwright also issued estimates for Innoviva’s Q3 2026 earnings at $0.51 EPS and FY2026 earnings at $2.23 EPS.

INVA has been the topic of several other research reports. Wall Street Zen lowered Innoviva from a “buy” rating to a “hold” rating in a research note on Sunday, May 17th. BTIG Research reiterated a “buy” rating and issued a $42.00 price objective on shares of Innoviva in a research report on Tuesday, May 26th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a research report on Friday, March 27th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Innoviva Stock Down 0.7%

NASDAQ INVA opened at $21.35 on Wednesday. The stock has a fifty day moving average of $22.89 and a 200-day moving average of $21.76. The stock has a market capitalization of $1.58 billion, a P/E ratio of 3.55 and a beta of 0.35. Innoviva has a 52 week low of $16.52 and a 52 week high of $25.15. The company has a debt-to-equity ratio of 0.19, a quick ratio of 20.07 and a current ratio of 21.13.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.01. Innoviva had a return on equity of 33.33% and a net margin of 119.89%.The firm had revenue of $97.99 million for the quarter, compared to the consensus estimate of $101.57 million.

Institutional Trading of Innoviva

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Innoviva by 6.6% in the 1st quarter. Bank of America Corp DE now owns 1,619,994 shares of the biotechnology company’s stock worth $37,746,000 after purchasing an additional 100,791 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Innoviva during the first quarter worth $3,081,000. California State Teachers Retirement System increased its holdings in Innoviva by 42.2% in the first quarter. California State Teachers Retirement System now owns 74,468 shares of the biotechnology company’s stock valued at $1,735,000 after purchasing an additional 22,103 shares during the last quarter. Empowered Funds LLC increased its holdings in Innoviva by 125.2% in the first quarter. Empowered Funds LLC now owns 168,055 shares of the biotechnology company’s stock valued at $3,916,000 after purchasing an additional 93,424 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Innoviva by 7.4% in the first quarter. The Manufacturers Life Insurance Company now owns 31,971 shares of the biotechnology company’s stock valued at $745,000 after buying an additional 2,216 shares during the period. Institutional investors own 99.12% of the company’s stock.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.